Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Lundbeck
Lundbeck
Otsuka and Lundbeck report data from three PTSD treatment trials
Clinical Trials Arena
Wed, 05/29/24 - 11:52 am
Otsuka
Lundbeck
PTSD
clinical tirals
brexpiprazole-sertraline
3 patent expirations in 2024 and how companies are pivoting
Pharma Voice
Wed, 04/17/24 - 11:13 am
patents
patent cliff
Bayer
J&J
Xarelto
Novo Nordisk
Victoza
Otsuka
Lundbeck
Abilify
Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses
Fierce Pharma
Tue, 01/23/24 - 11:08 am
Lundbeck
Charl van Zyl
Pharma CEOs
Vyepti
Rexulti
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
Pharma Voice
Fri, 08/11/23 - 09:55 am
Lundbeck
Pharma CEOs
Deborah Dunsire
Lundbeck replaces retiring CEO Deborah Dunsire with UCB exec after breaking sales record
Fierce Pharma
Tue, 06/27/23 - 10:17 am
Lundbeck
Pharma CEOs
Deborah Dunshire
Charl van Zyl
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Thu, 05/11/23 - 08:53 pm
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Mon, 05/1/23 - 10:04 am
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Sun, 04/16/23 - 11:17 pm
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Thu, 03/30/23 - 10:02 am
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
The Top New York Biopharma Companies Hiring Now
BioSpace
Mon, 01/9/23 - 10:58 pm
New York
hirings
Regeneron
Lundbeck
Schrödinger
FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
Fierce Pharma
Tue, 09/13/22 - 10:50 am
Otsuka
Lundbeck
schizophrenia
FDA
bipolar disorder
Abilify Maintena
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Thu, 08/18/22 - 12:32 pm
Lundbeck
earnings
migraines
CGRPs
Vyepti
Tracking mental health: Lundbeck partnership debuts US mapping dashboard tool
Endpoints
Sun, 02/20/22 - 11:51 am
Lundbeck
mental health
COVID-19
Amid crowded migraine market, Lundbeck goes its own way
Pharmaforum
Mon, 11/15/21 - 10:42 am
Lundbeck
migraines
Lu AG09222
Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility
Endpoints
Fri, 11/12/21 - 10:39 am
Lundbeck
R&D
layoffs
Vyepti
migraines
India
Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research
Pharmaforum
Mon, 09/20/21 - 10:59 pm
Lundbeck
Inscopix
CNS
R&D
Lundbeck sells off flopped Alzheimer's drug as Aduhelm approval ups interest
Fierce Biotech
Fri, 07/2/21 - 11:05 am
Lundbeck
Denovo Biopharma
Alzheimer's disease
Pages
1
2
3
4
5
6
7
next ›
last »